期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤细胞固有Toll样受体9信号通路的研究进展 被引量：1

Research progress of TLR9 inherent signaling pathways in tumor cells
原文传递
导出
摘要 Toll样受体（TLR）9与其配体非甲基化胞嘧啶-鸟嘌呤二核苷酸序列的DNA（CpGDNA）特异结合后启动下游信号级联，TLR9信号活化受颗粒体蛋白、可溶性核酸感应蛋白（HMGBl）和可溶性TLR9调控。TLR9不再局限表达于免疫细胞，还在多系统肿瘤细胞中表达，并参与维系与促进肿瘤细胞的恶性生物学行为。肿瘤细胞固有TLR9信号通路功能的阐明将为肿瘤控制提供新思路。 Specific activation of toll-Like Receptor 9 （ TLR9 ） by ligand CpG DNA/ODN can initiate downstream signaling. The activation of TLR9 signaling is regulated by Granulin, high-mobility group box-1 （HMGB1） and soluble TLRg. Interestingly, TLR9 is no longer only presented in the immune cells, but also expressed in many kinds of tumor cells. TLR9 is involved inmaintaining and promoting the malignant biological behaviors of tumor cells. Elucidation of the function of TLR9 inherent signaling pathways in the tumor cells will provide a novel idea for oncotherapy.
作者 费广茹 任涛
机构地区 同济大学附属东方医院呼吸科
出处 《国际肿瘤学杂志》 CAS 2012年第11期834-837,共4页 Journal of International Oncology
基金 基金项目：上海市青年科技启明星计划（跟踪）（10QHl402000） 上海市浦东新区卫生系统学科带头人计划（PWRd2010-01）、上海市科委基础研究重点项目（11JCl410900）
关键词 肿瘤 寡核苷酸类 TOLL样受体9 Neoplasms Oligonucleotides Toll-Like receptor 9
分类号 R730.2 [医药卫生—肿瘤]
  • 相关文献

参考文献1

二级参考文献27

  • 1Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
  • 2Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzese JL. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 2000; 95:17-31.
  • 3Real FX, Cibrian-Uhalte E, Martinelli P. Pancreatic cancer development and progression: remodeling the model. Gastroenterology 2008; 135:724-728.
  • 4Tanase CP, Dima S, Mihai M, Raducan E, Nicolescu MI, Albulescu L, Voiculescu B, Dumitrascu T, Cruceru LM, Leabu M, Popescu I, Hinescu ME. Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma. J Mol Histo12009; 40:23-29.
  • 5Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Bflchler MW, Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358:1576-1585.
  • 6Jungert K, Buck A, von Wichert G, Adler G, Konig A, Buchholz M, Gress TM, Ellenrieder V. Spl is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res 2007; 67:1563-1570.
  • 7Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
  • 8O'Neill LA. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol2006; 18:3-9.
  • 9Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5: 975-979.
  • 10Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Fertone S, Morton DL, Irie RF, Hoon DS. Activation of Toll- like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther 2008; 7:3642-3653.

共引文献9

同被引文献6

引证文献1

二级引证文献3

国际肿瘤学杂志
2012年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部